First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business segment, accelerates early drug candidates into...

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.